HORMONAL INFLUENCE ON BREAST CANCER DEVELOPMENT AND PROGRESSION: MOLECULAR INSIGHTS AND THERAPEUTIC ADVANCES
Abstract
Breast cancer is the most commonly diagnosed malignancy among women globally, with hormonal factors playing a pivotal role in its pathogenesis and progression. Estrogen and progesterone, the primary female sex hormones, are deeply implicated in tumor development through their interaction with nuclear hormone receptors and subsequent gene regulation. This article explores the molecular mechanisms by which hormones influence breast cancer initiation and evolution. It also reviews current hormonal therapies, including selective estrogen receptor modulators (SERMs), aromatase inhibitors, and emerging targeted approaches. Moreover, recent statistics, clinical trial outcomes, and global treatment disparities are examined to present a comprehensive understanding of hormone-driven breast cancer management.
Keywords
Breast cancer, estrogen, progesterone, hormone receptors, SERMs, aromatase inhibitors, hormonal therapy, molecular oncology, targeted treatment, endocrine resistance.
References
- Khodjayeva G.M., Saidova R.N. (2023). Ayollarda ko‘krak bezi saratoni: gormonlar va davolash yondashuvlari. Tashkent: O‘zbekiston onkologiya markazi nashriyoti.
- Boboyeva Z.M. (2022). Endokrin onkologiyaning zamonaviy yondashuvlari. Buxoro: BuxDTU ilmiy jurnali.
- International Sources:
- World Health Organization (2023). Breast Cancer Fact Sheet. Geneva: WHO Press.
- Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2021). Long-term effects of endocrine therapy of breast cancer. The Lancet, 397(10287), 1445–1458.
- Finn R.S., et al. (2016). Palbociclib and Letrozole in Advanced Breast Cancer. New England Journal of Medicine, 375(20), 1925–1936.
- Gnant M., et al. (2017). Everolimus in hormone receptor-positive advanced breast cancer. The Lancet Oncology, 18(7), 963–975.
- Osborne C.K., Schiff R. (2011). Mechanisms of endocrine resistance in breast cancer. Annual Review of Medicine, 62, 233–247.
- Ellis M.J., et al. (2022). ESR1 mutations and hormonal therapy resistance. Cancer Discovery, 12(3), 624–635.